

BIODELIVERY SCIENCES INTERNATIONAL INC  
Form SC 13D/A  
June 17, 2009

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### SCHEDULE 13D

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO  
FILED PURSUANT TO RULE 13d-2(a)

(Amendment No. 1)\*

BioDelivery Sciences International, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

09060J106

(CUSIP Number)

Stephen M. Schultz, Esq.

Kleinberg, Kaplan, Wolff & Cohen, P.C.

551 Fifth Avenue, New York, New York 10176

Tel: (212) 986-6000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

June 4, 2009

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box o.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13D/A

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see the Notes*).

---

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13D/A

1. NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Elliott Associates, L.P.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a)  X

(b)  O

3. SEC USE ONLY

4. SOURCE OF FUNDS\*

WC

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)  O

6. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

7. SOLE VOTING POWER

4,075,350

8. SHARED VOTING POWER

0

9. SOLE DISPOSITIVE POWER

4,075,350

10. SHARED DISPOSITIVE POWER

0

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,075,350

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)

EXCLUDES CERTAIN SHARES\*  O

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

18.8%

14. TYPE OF REPORTING PERSON\*

PN

**\*SEE INSTRUCTIONS BEFORE FILLING OUT!**

---

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13D/A

1. NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Elliott International, L.P.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a)  X

(b)  O

3. SEC USE ONLY

4. SOURCE OF FUNDS\*

WC

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)  O

6. CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands, British West Indies

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

7. SOLE VOTING POWER

0

8. SHARED VOTING POWER

262,845

9. SOLE DISPOSITIVE POWER

0

10. SHARED DISPOSITIVE POWER

262,845

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

262,845

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)

EXCLUDES CERTAIN SHARES\*  O

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

1.4%

14. TYPE OF REPORTING PERSON\*

PN

**\*SEE INSTRUCTIONS BEFORE FILLING OUT!**

---

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13D/A

1. NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Elliott International Capital Advisors Inc.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a)  X

(b)  O

3. SEC USE ONLY

4. SOURCE OF FUNDS\*

OO

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)  O

6. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

7. SOLE VOTING POWER

0

8. SHARED VOTING POWER

262,845

9. SOLE DISPOSITIVE POWER

0

10. SHARED DISPOSITIVE POWER

262,845

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

262,845

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)

EXCLUDES CERTAIN SHARES\*  O

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

1.4%

14. TYPE OF REPORTING PERSON\*

CO

**\*SEE INSTRUCTIONS BEFORE FILLING OUT!**

---

## Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13D/A

This statement is filed with respect to the shares of the common stock, \$0.001 par value (the "Common Stock"), of BioDelivery Sciences International, Inc. (the "Issuer"), beneficially owned by Elliott Associates, L.P. and its wholly-owned subsidiaries ("Elliott"), Elliott International, L.P. ("Elliott International"), and Elliott International Capital Advisers Inc. ("EICA" and collectively, the "Reporting Persons") as of June 17, 2009 and amends and supplements the Schedule 13D filed on August 23, 2006 (the "Schedule 13D"). Except as set forth herein, the Schedule 13D is unmodified.

### **ITEM 1. Security and Issuer.**

Item 1 of the Schedule 13D has been supplemented by adding the following:

The Issuer's principal executive office is located at 801 Corporate Center Drive, Suite 210, Raleigh, North Carolina, 27607.

### **ITEM 2. Identity and Background.**

Item 2 of the Schedule 13D has been supplemented by adding the following:

On June 4, 2009, the manager of CDC IV, LLC ("CDC") delegated to Manchester Securities Corp. ("Manchester"), a wholly owned subsidiary of Elliott, all of its rights and authority with respect to the investment decisions relating to the Common Stock and the warrants to acquire Common Stock owned of record by CDC IV. Therefore, Elliott may be deemed to be the beneficial owner within the meaning of Rule 13d-3 of Common Stock and warrants to acquire Common Stock owned of record by CDC IV.

### **ITEM 5. Interest in Securities of the Issuer.**

(a) Elliott owns 175,230 shares of Common Stock through a wholly-owned subsidiary, The Liverpool Limited Partnership. Elliott may also be deemed to be the beneficial owner of an additional 3,900,120 shares of Common Stock beneficially owned by CDC IV (the "CDC IV Shares"), consisting of: (i) 1,395,000 shares of Common Stock held by CDC IV and (ii) warrants held by CDC IV exercisable for 2,505,120 shares of Common Stock ("Warrants"). As described, above Manchester has investment discretion with respect to the CDC IV Shares and Warrants. Therefore, Elliott may be deemed to be the beneficial owner of an aggregate of 4,075,350 shares of Common Stock, constituting 18.8% of all of the outstanding shares of Common Stock.

Elliott International and EICA beneficially own an aggregate of 262,845 shares of Common Stock, constituting 1.4% of all of the outstanding shares of Common Stock.

The stock ownership reported in this paragraph (a) of Item 5 is as of June 17, 2009.

(b) Elliott has the power to vote or direct the vote of, and to dispose or direct the disposition of, the shares of Common Stock beneficially owned by it.

Elliott International has the shared power with EICA to vote or direct the vote of, and to dispose or direct the disposition of, the shares of Common Stock owned by Elliott International. Information regarding each of Elliott International and EICA is set forth in Item 2 of this Schedule 13D and is expressly incorporated by reference herein.

(c) A list of the transactions in the Issuer's Common Stock that were effected by Elliott on behalf of CDC IV during the past sixty days is attached hereto as Appendix I.

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13D/A

(d) Except for the CDC IV Shares and the Warrants, no person other than Elliott has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock beneficially owned by Elliott.

No person other than Elliott International and EICA has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock beneficially owned by Elliott International and EICA.

(e) Not applicable.

**ITEM 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Except as described in Item 2, there are no contracts, arrangements, understanding or relationships with respect to the securities of the Issuer among the Reporting Persons and any other person.

**Item 7. Material to Be Filed as Exhibits**

The following documents are filed as exhibits:

Appendix I: List of the transactions in the Issuer's Common Stock that were effected by the Reporting Persons during the past sixty days.

---

**SIGNATURES**

After reasonable inquiry and to the best of its knowledge and belief, the undersigned each certifies that the information with respect to it set forth in this statement is true, complete and correct.

Dated: June 17, 2009

ELLIOTT ASSOCIATES, L.P.

By: Elliott Capital Advisors, L.P., as General Partner

By: Braxton Associates, Inc., as General Partner

By: /s/ Elliot Greenberg

Elliot Greenberg,

Vice President

ELLIOTT INTERNATIONAL, L.P.

By: Elliott International Capital Advisors Inc.,

as Attorney-in-Fact

By: /s/ Elliot Greenberg

Elliot Greenberg,

Vice President

ELLIOTT INTERNATIONAL CAPITAL ADVISORS INC.

By: /s/ Elliot Greenberg

Elliot Greenberg,

Vice President

---



## APPENDIX I

## LIST OF TRANSACTIONS

Transactions Effected by Manchester on behalf of CDC IV in Common Stock during the past sixty days:

Date of transaction	Amount of securities Sold	Price per share or unit (excluding commissions)	Where and how the transaction was effected
06/15/09	39,263	\$6.9000	Open Market
06/15/09	400	\$6.9050	Open Market
06/15/09	100	\$6.9100	Open Market
06/15/09	3,527	\$6.9200	Open Market
06/15/09	423	\$6.9300	Open Market
06/15/09	2,777	\$6.9400	Open Market
06/15/09	5,100	\$6.9500	Open Market
06/15/09	4,500	\$6.9600	Open Market
06/15/09	200	\$6.9650	Open Market
06/15/09	100	\$6.9700	Open Market
06/15/09	11,600	\$6.9800	Open Market
06/15/09	100	\$6.9900	Open Market
06/15/09	31,694	\$7.0000	Open Market
06/15/09	2,900	\$7.0050	Open Market
06/15/09	5,100	\$7.0100	Open Market
06/15/09	500	\$7.0120	Open Market
06/15/09	300	\$7.0125	Open Market
06/15/09	5,100	\$7.0200	Open Market
06/15/09	2,800	\$7.0300	Open Market
06/15/09	11,800	\$7.1000	Open Market
06/15/09	5,988	\$7.1100	Open Market
06/15/09	800	\$7.1200	Open Market
06/15/09	100	\$7.1300	Open Market
06/15/09	27,699	\$7.2000	Open Market
06/15/09	1,300	\$7.2050	Open Market
06/15/09	300	\$7.2075	Open Market
06/15/09	3,779	\$7.2100	Open Market
06/15/09	300	\$7.2175	Open Market
06/15/09	1,700	\$7.2200	Open Market
06/15/09	1,000	\$7.2250	Open Market
06/15/09	5,900	\$7.2275	Open Market
06/15/09	1,951	\$7.2300	Open Market
06/15/09	400	\$7.2350	Open Market
06/15/09	1,000	\$7.2400	Open Market
06/15/09	2,000	\$7.2475	Open Market
06/15/09	1,400	\$7.2500	Open Market
06/15/09	85,586	\$7.5000	Open Market

---

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13D/A

06/15/09	500	\$7.5075	Open Market
06/15/09	18,968	\$7.5100	Open Market
06/15/09	300	\$7.5150	Open Market
06/15/09	600	\$7.5175	Open Market
06/15/09	8,100	\$7.5200	Open Market
06/15/09	200	\$7.5250	Open Market
06/15/09	3,170	\$7.5300	Open Market
06/15/09	680	\$7.5400	Open Market
06/15/09	100	\$7.5450	Open Market
06/15/09	7,459	\$7.5500	Open Market
06/15/09	100	\$7.5550	Open Market
06/15/09	3,400	\$7.5800	Open Market
06/15/09	12,030	\$7.6000	Open Market
06/15/09	8,650	\$7.6100	Open Market
06/15/09	100	\$7.6200	Open Market
06/15/09	700	\$7.6300	Open Market
06/15/09	800	\$7.6400	Open Market
06/15/09	10,800	\$7.6500	Open Market
06/15/09	4,100	\$7.6600	Open Market
06/15/09	300	\$7.6800	Open Market
06/15/09	70	\$7.6900	Open Market
06/15/09	300	\$7.7550	Open Market
06/15/09	50	\$7.7575	Open Market
06/15/09	1,550	\$7.7800	Open Market
06/15/09	1,200	\$7.7900	Open Market
06/15/09	1,600	\$7.7950	Open Market
06/15/09	21,563	\$7.8000	Open Market
06/15/09	300	\$7.8050	Open Market
06/15/09	400	\$7.8070	Open Market
06/15/09	300	\$7.8075	Open Market
06/15/09	9,350	\$7.8100	Open Market
06/15/09	500	\$7.8200	Open Market
06/15/09	1,500	\$7.8250	Open Market
06/15/09	1,150	\$7.8275	Open Market
06/15/09	1,500	\$7.8300	Open Market
06/15/09	2,750	\$7.8325	Open Market
06/15/09	4,200	\$7.8400	Open Market
06/15/09	700	\$7.8450	Open Market
06/15/09	200	\$7.8475	Open Market
06/15/09	1,327	\$7.8500	Open Market
06/15/09	3,100	\$7.8600	Open Market
06/15/09	100	\$7.8650	Open Market
06/15/09	2,230	\$7.8675	Open Market
06/15/09	800	\$7.8700	Open Market

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13D/A

06/15/09	1,950	\$7.8900	Open Market
06/15/09	7,470	\$7.8950	Open Market
06/15/09	2,000	\$7.8975	Open Market
06/15/09	1,810	\$7.9000	Open Market
06/15/09	600	\$7.9300	Open Market
06/15/09	850	\$8.2500	Open Market
06/15/09	10,000	\$8.2900	Open Market
06/15/09	4,036	\$8.4002	Open Market
06/16/09	23,020	\$6.3000	Open Market
06/16/09	1,980	\$6.3100	Open Market
06/16/09	29,675	\$6.3500	Open Market
06/16/09	200	\$6.3600	Open Market
06/16/09	5,400	\$6.3700	Open Market
06/16/09	12,949	\$6.3800	Open Market
06/16/09	1,776	\$6.4000	Open Market
06/16/09	25,000	\$6.4500	Open Market
06/16/09	911	\$6.4800	Open Market
06/16/09	14,589	\$6.5000	Open Market
06/16/09	400	\$6.5100	Open Market
06/16/09	28,148	\$6.6000	Open Market
06/16/09	10,290	\$6.6200	Open Market
06/16/09	4,651	\$6.6500	Open Market
06/16/09	8,911	\$7.0000	Open Market
06/16/09	100	\$7.0100	Open Market
06/16/09	1,000	\$7.0200	Open Market